Progenics’ monoclonal antibodies constitute a non-antibiotic treatment strategy that is designed to block the harmful effects of the disease-causing toxins produced by C difficile.
Progenics Pharma founder, CEO chief science officer said that they were honored to receive this competitive NIH award and were gratified that NIH elected to support their program based on its scientific merit and therapeutic potential.
Progenics’ humanised monoclonal antibodies are designed to block the cytotoxic effects of C difficile toxins and enable the normal bacteria in the colon to become reestablished.
Progenics claimed that in laboratory studies, the humanised monoclonal antibodies neutralised the cell-killing activities of the toxins produced by both conventional and hypervirulent strains of C difficile.